chloroquine and derivatives - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.08 [0.95, 1.23]< 111%3 studies (3/-)12.1 %some concernnot evaluable moderatecrucial-
deaths 1.08 [0.97, 1.19]< 10%13 studies (13/-)8.0 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.08 [0.95, 1.23]< 111%3 studies (3/-)12.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.20 [0.83, 1.72]< 10%3 studies (3/-)16.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.09 [0.81, 1.46]> 10%2 studies (2/-)71.4 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.01 [0.78, 1.30]> 10%4 studies (4/-)52.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 0.97 [0.69, 1.37]> 10%1 study (1/-)43.2 %lownot evaluable highimportant-
clinical improvement (7-day) 1.16 [0.84, 1.61]> 10%1 study (1/-)81.4 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.01 [0.79, 1.28]> 10%2 studies (2/-)52.7 %some concernnot evaluable moderateimportant-
death or ventilation 1.13 [1.03, 1.24]< 10%5 studies (5/-)0.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.20 [0.83, 1.73]> 143%4 studies (4/-)83.7 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 2.40 [0.26, 22.51]> 10%1 study (1/-)77.7 %some concernnot evaluable moderateimportant-
viral clearance 1.17 [0.76, 1.79]> 10%2 studies (2/-)76.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.09 [0.95, 1.26]> 10%2 studies (2/-)88.8 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.20 [0.60, 2.40]> 10%1 study (1/-)69.7 %some concernnot evaluable moderateimportant-
ICU admission 0.83 [0.35, 1.95]< 10%1 study (1/-)66.8 %some concernnot evaluable moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
serious adverse events 1.26 [0.56, 2.84]< 10%1 study (1/-)28.7 %lownot evaluable highimportant-
adverse events 1.32 [1.03, 1.70]< 10%6 studies (6/-)1.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.